Atlas Trials

A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4

Clinical trial NCT02371408 · UNKNOWN

Trial details

NCT number
NCT02371408
Sponsor
Pharco Pharmaceuticals
Status
UNKNOWN
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Chronic Hepatitis C
Start date
2015-01-01
Primary completion
2016-01-01
Enrollment
300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.